Oruka Therapeutics, Inc. ORKA
Set alert
As of Nov 2, 10:30 AM ET
- YTD
- +216.72%
- 1 year
- +240.78%
- Open
- 98.85
- Prev close
- 96.87
- Mkt cap
- 6.36B
- Vol
- 102.86K
- Avg vol
- 892.48K
- EPS
- -2.04
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 95.32
- High
- 99.83
- Forward P/E
- -33.85
- Beta
- -0.11
- Short ratio
- 5.86
- Inst. own
- 116.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 88.63
- 200-d avg
- 68.91
- 1y target
- 156.17
5D chart
Events in this range
- Oct 27, 2026Rating: Wedbush · Outperform → Outperform
- Oct 27, 2026Rating: Guggenheim · Buy → Buy
Signals (111)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 9:50 AM | 41 minutes ago |
| SMA: Bearish | Nov 2, 9:40 AM | 51 minutes ago |
| RSI: Overbought | Nov 2, 9:30 AM | 1 hour ago |
| RSI: Overbought | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:10 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:05 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| RSI: Oversold | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 5 days ago |
| RSI: Overbought | Oct 28, 11:00 AM | 5 days ago |
| RSI: Overbought | Oct 28, 10:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:35 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:25 AM | 6 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:25 AM | 6 days ago |
News
-
6 days ago benzinga.com
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
-
6 days ago benzinga.com
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target
Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.
-
6 days ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
6 days ago marketbeat.com
Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study
Oruka Therapeutics NASDAQ: ORKA reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The company said its…
6 days ago seekingalpha.com
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript
6 days ago benzinga.com
Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial
Oruka Therapeutics Inc. (NASDAQ:ORKA) on Monday reported positive Week 16 results from its EVERLAST-B Phase 2b clinical trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.
6 days ago benzinga.com
Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial
Oruka Therapeutics reported positive Week 16 Phase 2b data for ORKA-001, showing 61% complete skin clearance in plaque psoriasis patients.
1 week ago benzinga.com
Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday
U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.
-
1 week ago benzinga.com
Oruka Reports Week 16 Phase 2b Results For ORKA-001 In Plaque Psoriasis, With 61% PASI 100 And 86% PASI 90 Response Rates; ORKA-001 On Track To Advance Into Phase 3 Trials In 1H 2027
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-AContinued favorable safety and tolerability profile consistent with the IL-23p19 classORKA-001 on…
1 week ago globenewswire.com
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on…
-
2 weeks ago benzinga.com
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target
Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy
Oruka Therapeutics reports positive week 28 results from its Phase 2a trial for plaque psoriasis treatment ORKA-001.
-
1 month ago benzinga.com
Oruka Therapeutics Announces Week 28 Results From Its EVERLAST-A Phase 2A Trial Of ORKA-001 In Moderate-To-Severe Plaque Psoriasis; ORKA-001 Maintained Favorable Safety And Tolerability Profile Through Week 28; 16-Week EVERLAST-B Data Expected In Q4 2026
Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis."These Week 28 results, with responses…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
-
2 months ago benzinga.com
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
-
2 months ago benzinga.com
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
-
2 months ago benzinga.com
Oruka Therapeutics Q2 EPS $(0.55) Misses $(0.51) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.51) by 7.84 percent. This is a 19.57 percent decrease over losses of…
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
-
3 months ago benzinga.com
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
4 months ago benzinga.com
Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares
Oruka Therapeutics stock falls after hours after Fairmount sells a $300 million stake via SEC filing.
-
4 months ago benzinga.com
UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $100 to $130.
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
4 months ago benzinga.com
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other gaining stocks include DFTX, HIVE, SSTK, BWIN, ICCM, ORKA, CHRN, UMC,…
-
5 months ago benzinga.com
Oruka Therapeutics Expands ORKA-001 License To All Indications, Adding Future IBD Rights Under Paragon Amendment
On May 29, 2026, Oruka Therapeutics, Inc. (the "Company") entered into the First Amendment to IL-23 License Agreement (the "Amendment"), amending the IL-23 License Agreement dated as of December 17,…
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
-
5 months ago benzinga.com
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
-
5 months ago benzinga.com
Oruka Therapeutics Q1 EPS $(0.48) Beats $(0.55) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.55) by 12.73 percent. This is a 20 percent decrease over losses of…
-
6 months ago benzinga.com
Oruka Therapeutics Files Prospectus For Offering 9.66M Common Shares
https://www.sec.gov/Archives/edgar/data/907654/000121390026049372/ea0288174-424b5_oruka.htm
6 months ago benzinga.com
CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.
6 months ago benzinga.com
XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY,…
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
6 months ago benzinga.com
Microsoft To $500? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and upgrades/downgrades on our analyst ratings page.
6 months ago benzinga.com
Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
11 months ago benzinga.com
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
11 months ago benzinga.com
AutoZone To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday
AutoZone To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday
1 year ago benzinga.com
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago benzinga.com
Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket
Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket
1 year ago benzinga.com
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago benzinga.com
PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago benzinga.com
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
1 year ago benzinga.com
Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket
Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket